Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IPH2102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| IPH2102 at 1 mg/kg | EXPERIMENTAL | lirilumab (IPH2102/BMS986015) at 1 mg/kg |
| IPH2102 at 0.1 mg/kg | EXPERIMENTAL | lirilumab (IPH2102/BMS986015) at 0.1 mg/kg |
| Placebo (Normal saline solution) | PLACEBO_COMPARATOR | Normal saline solution |
| Name | Type | Description |
|---|---|---|
| IPH2102 at 0.1 mg/kg | DRUG | every 3 months |
| IPH2102 at 1 mg/kg | DRUG | every 4 weeks |
| Placebo (normal saline solution) | DRUG | every 4 weeks |
Inclusion Criteria: 1. Primary or secondary Acute Myeloid Leukemia (AML, defined according to WHO 2008 criteria), in first CR/CRi (according to the revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Stand...
IPH2102 is an investigational small molecule developed by Innate Pharma S.A. (ticker IPHA) for the treatment of acute myeloid leukemia, a cancer of the blood and bone marrow. It has been studied as a maintenance treatment in older patients with this disease.
IPH2102 was studied as a maintenance treatment in acute myeloid leukemia, meaning it was given to patients after their disease had been brought under control, with the goal of delaying relapse. The Phase 2 trial enrolled patients aged 60 years and older in France.
IPH2102 is developed by Innate Pharma S.A., a biopharmaceutical company whose ticker symbol is IPHA. Innate Pharma sponsored the clinical program evaluating the drug in acute myeloid leukemia.
IPH2102 is in Phase 2 development. It is investigational and has not been approved by the FDA. One Phase 2 trial has been completed, and no trials are currently active.
IPH2102 has been evaluated in one completed Phase 2 trial, NCT01687387, also called EFFIKIR. The study was a randomized, double-blind, placebo-controlled trial of anti-KIR monoclonal antibody maintenance treatment in acute myeloid leukemia, enrolling 152 patients in France.